期刊
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
卷 467, 期 11, 页码 2932-2938出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1007/s11999-009-0814-x
关键词
-
资金
- The Nakatomi Foundation
- Ministry of Education, Culture, Sports, Science and Technology of Japan [20591751]
- Grants-in-Aid for Scientific Research [20591751] Funding Source: KAKEN
Several lines of evidence suggest cyclooxygenase-2 (COX-2) overexpression may be a causal factor for tumor growth and metastasis. However, there is no evidence COX-2 expression in a primary tumor correlates with clinical outcome of osteosarcoma. We examined expression levels of COX-2 immunohistochemically in 51 patients with extremity osteosarcoma who completed standard therapy and obtained complete initial regression of the tumor. Correlation of the positivity of staining with prognosis was analyzed. COX-2 was expressed in most of the cases. We found no correlation between COX-2 staining intensity and variables such as gender, age, anatomic site, necrosis after chemotherapy, and surgical stage. Strong COX-2 expression was associated with low metastasis-free survival. Age older than 20 years and strong COX-2 expression independently predicted increased risk of metastasis. Among seven patients with resectable lung metastasis, all three with greater COX-2 expression in the metastatic lesion than that in a primary site died of the disease. Our preliminary data suggest COX-2 overexpression in the primary tumor correlates with the occurrence of distant metastasis in patients with osteosarcoma and also may affect postmetastatic survival. Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据